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Gerard Conway, a colleague at the adult DSD clinic at 
UCLH, recently said: “If the phenotype doesn’t make 
sense, think of SF-1.” This may not always be true, but 
steroidogenic factor-1 (SF-1/NR5A1)-related pheno-
types have expanded greatly in recent years, and the re-
port of Swartz et al. [1] in this issue of Hormone Research 
in Paediatrics adds to the emerging picture.
SF-1 (officially known as NR5A1, but hereafter called 
SF-1) was originally discovered by Keith Parker and Ken-
Ichirou Morohashi in the early 1990s following the search 
for a master-regulator of steroidogenesis. SF-1 is an or-
phan nuclear receptor that controls many aspects of ad-
renal and reproductive development and function. Dis-
ruption of the gene encoding Sf-1 in the mouse results in 
adrenal underdevelopment and testicular dysgenesis. 
When 2 children with a similar phenotype were reported 
around the turn of the century, it seemed severe disrup-
tion of SF-1 would be an important differential diagnosis 
in paediatric endocrinology, but children with this condi-
tion would probably be extremely rare.
The past decade, however, has seen a massive expansion 
in both the number of reported children and families with 
clinically significant variations in SF-1 and the range of as-
sociated phenotypes [2]. Heterozygous loss-of-function 
variations in SF-1 have been described throughout the 
spectrum of 46,XY disorders of sex development (DSD), 
including testicular dysgenesis with or without müllerian 
structures, disordered androgen production, penoscrotal 
hypospadias, progressive androgenisation at puberty, and 
even male factor infertility. Although women can harbour 
SF-1 variants and pass them on in a sex-limited dominant 
fashion (that mimics X-linked inheritance), disruption of 
SF-1 is also associated with primary ovarian insufficiency 
and early menopause, although the penetrance of the phe-
notype is variable. Severe disruption of SF-1 can rarely be 
associated with primary adrenal insufficiency in 46,XX 
girls. However, to date, adrenal function has been pre-
served in the vast majority of individuals with heterozy-
gous SF-1 variants, although long-term studies are needed 
to know whether this might deteriorate with age.
This year, the SF-1 story has taken a new twist, with 
several reports showing that alterations in SF-1 can be as-
sociated with 46,XX ovotesticular DSD (OTDSD) and 
46,XX testicular DSD (TDSD) (“XX males”). Remark-
ably, all affected individuals had exactly the same change, 
a heterozygous p.Arg92Trp variant.
In the first published report, Bashamboo et al. [3] de-
scribed 2 sisters with OTDSD, 2 men with TDSD, and a 
family with a 46,XX child raised male and a 46,XY child 
raised female. These individuals and families came from 
diverse genetic backgrounds: European, African, Hispanic, 











   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















ported 3 apparently unrelated individuals with OTDSD or 
TDSD from Belgium/the Netherlands, and Igarashi et al. 
[5] described 2 unrelated individuals with OTDSD/TDSD 
in Japan. Codon 92 is a critical amino acid in the “A-box” 
accessory DNA-binding region of SF-1. Laboratory studies 
suggest that the p.Arg92Trp variant alters repression of 
testis pathways, although data in robust biological systems 
are limited. Indeed, insertion of the specific p.Arg92Trp 
change into the mouse by CRISPR/Cas9 genome-editing 
does not produce a phenotype in the ovary [6]. Although 
many changes had arisen de novo, penetrance of the phe-
notype in humans is variable, with several 46,XX female 
carriers of the p.Arg92Trp change seemingly unaffected.
The report by Swartz et al. [1] in this edition of Hor-
mone Research in Paediatrics adds to the intrigue of 
the situation. Using whole-exome sequencing of individ-
uals with OTDSD, they have identified a heterozygous 
p.Arg92Gln variant (not p.Arg92Trp) in a child with 
46,XX OTDSD of American-European ancestry. This 
variant was inherited from her unaffected father. Of note, 
this specific change has been reported previously in a ho-
mozygous state in association with 46,XY DSD and adre-
nal insufficiency as well as in a 46,XX girl with adrenal 
insufficiency alone [7, 8]. Both these children came from 
Northern Turkey, and heterozygous carriers so far have 
been reported to be unaffected [5, 7].
These studies are providing fascinating insight into the 
role of SF-1 in human endocrine development but are 
also raising many questions. Variations in codon 92 can 
clearly alter human ovary development resulting in par-
tial or complete testis development. The report of 11 chil-
dren and adults with OTDSD/TDSD in the past few 
months alone, the de novo nature of the changes in many 
cases, and the complete absence of these variants in con-
trol databases all make this association genetically robust. 
However, many questions remain about the exact bio-
logical mechanism (or mechanisms) involved and why 
the phenotypic penetrance is variable. The human gonad 
is exquisitely sensitive to gene dosage effects during criti-
cal windows of development, possibly much more so than 
the mouse gonad. Other genetic, epigenetic, or environ-
mental modifiers or somatic changes may also influence 
the phenotype. Subtle imbalance of a sex-determining 
“switch” at a critical time in embryo development could 
have a big effect. Of course, this makes our task of provid-
ing appropriate information and counselling for young 
people and their families all the more difficult, but this is 
a challenge we must embrace. SF-1-related conditions are 
now an important part of paediatric endocrinology, and 
having multiple phenotypes associated with different 
variations in the same gene is a phenomenon that we are 
starting to observe for many genes, not just SF-1.
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